Chordate Medical (publ) ("Chordate" or "the company") has today received preliminary approval from Nasdaq Stockholm AB ("Nasdaq") regarding admission to trading of its shares on the Nasdaq First North Growth Market. Provided that Chordate formally applies for approval, fulfills the prevailing conditions and is finally approved by Nasdaq, it is deemed that the list change can be carried out with first trading day on Nasdaq being on February 15th, 2022. NGM SME, where the company's shares are listed, approved the Company's application for delisting on January 28th, 2022, with a preliminary last trading day on February 14th, 2022, provided that trading in the Company's shares can be admitted on Nasdaq First North Growth Market the following trading day.
As previously communicated, The Board believes that a change of trading venue for the company's shares to Nasdaq First North Growth Market will increase the knowledge of the company both in Sweden and internationally, making it easier for industrial investors to become shareholders, and have a positive impact on the company's relationships with partners and potential customers. Overall, a change of trading venue is considered to be positive for Chordate's development and completion of the stated exit strategy.
Provided that Chordate receives final approval from Nasdaq, the company's shares will continue to be traded under the short name CMH with the current ISIN code SE0009495559. Shareholders in Chordate will not have to take any action in the event of a change of trading venue.
Västra Hamnen Corporate Finance AB is Chordate's advisor regarding the planned list change and Certified Adviser. Wistrand Advokatbyrå AB is Chordate's legal advisor.
This disclosure was submitted for publication, through the contact person below, on January 31st, 2022, at 15:30 am CET.
For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277
The following documents can be retrieved from beQuoted
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM – SME (ticker: CMH). Read more atwww.chordate.com